Abstract
New evidence has dramatically demonstrated that only a minority of cancer cells has the capacity to proliferate extensively and form new tumors; these cells are called “tumor-initiating cells” or “cancer stem cells”. In this review, we focus on recent molecular insights into the nature of cancer stem cells in leukemia, leukemic stem cells (LSCs). LSCs arise not only from primitive hematopoietic stem cells (HSCs) with self-renewal capacity but also from committed progenitor cells that normally lack the ability to self-renew. These latter cells gain stem cell properties by reactivating a gene expression program similar to that functioning in normal HSCs. The self-renewal and differentiation capacities of normal primitive hematopoietic cells are controlled by complex signaling pathways involving Wnt/β-catenin, Pu.1/JunB and PI3K/Akt. These same mediators also participate in the leukemogenesis. In mice, administration of drugs such as rapamycin and anti-CD44 antibody, which target properties unique to LSCs, can selectively deplete these cells in vivo. The goal for this field is to design successful human leukemia therapies based on the targeting or manipulation of features specific to LSCs.
Keywords: Leukemic stem cells, hematopoietic stem cells, self-renewal capacity
Current Cancer Therapy Reviews
Title: The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Volume: 4 Issue: 3
Author(s): Kazuhito Naka, Masako Ohmura, Takayuki Hoshii, Teruyuki Muraguchi and Atsushi Hirao
Affiliation:
Keywords: Leukemic stem cells, hematopoietic stem cells, self-renewal capacity
Abstract: New evidence has dramatically demonstrated that only a minority of cancer cells has the capacity to proliferate extensively and form new tumors; these cells are called “tumor-initiating cells” or “cancer stem cells”. In this review, we focus on recent molecular insights into the nature of cancer stem cells in leukemia, leukemic stem cells (LSCs). LSCs arise not only from primitive hematopoietic stem cells (HSCs) with self-renewal capacity but also from committed progenitor cells that normally lack the ability to self-renew. These latter cells gain stem cell properties by reactivating a gene expression program similar to that functioning in normal HSCs. The self-renewal and differentiation capacities of normal primitive hematopoietic cells are controlled by complex signaling pathways involving Wnt/β-catenin, Pu.1/JunB and PI3K/Akt. These same mediators also participate in the leukemogenesis. In mice, administration of drugs such as rapamycin and anti-CD44 antibody, which target properties unique to LSCs, can selectively deplete these cells in vivo. The goal for this field is to design successful human leukemia therapies based on the targeting or manipulation of features specific to LSCs.
Export Options
About this article
Cite this article as:
Naka Kazuhito, Ohmura Masako, Hoshii Takayuki, Muraguchi Teruyuki and Hirao Atsushi, The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294267
DOI https://dx.doi.org/10.2174/157339408785294267 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Current Pharmaceutical Biotechnology Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells
Current Topics in Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Lead Generation for Human Mitotic Kinesin Eg5 Using Structure-based Virtual Screening and Validation by In-vitro and Cell-based Assays
Current Computer-Aided Drug Design Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal Recent Studies on Natural Products as Anticancer Agents
Current Topics in Medicinal Chemistry The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System
Current Biotechnology Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Modulation of Antibiotic Efflux in Bacteria
Current Medicinal Chemistry - Anti-Infective Agents The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry